GSK Annual Report 2002

More documents

Recommendations

Info

160 GlaxoSmithKline Index O Oncology and emesis 7-9,16,21,55,56,67-69,82, 144-148 Operating and financial review and prospects 51-72 Oral care 6,9,13,14,22,57,69,86,148 Other operating income/(expense) 57,58,69,70, 76,89,126,142 Outlook 53,64 Over-the-counter (OTC) medicines 6,9,11,13,57,69 82,86,148 P Patents 3,4,10-13,23,54,64,65,84,95,103-107,130 Payment policies 62 Pension and other post-retirement benefits 43-45,50,59,60,72,78,84,92,97,98, 114-118,123,126,128-133,136,137 Pharmaceuticals approvals and submissions 11,12,19 business sector 6,86-88,132,134,135,148 competition 10 manufacturing and supply 13,14 marketing and distribution 13 products 7-14,19,53,54,58,64 sales 8,10,13,37,52-56,64-69,86, 142-148 research and development 10,14-22,25,37,52, 57,58,62,69,76,82,83,114,126,130,136, 142,150 regulation 11-12 patents and trade marks 5,23 Pipeline 14-17 Presentation of financial statements 82 Price controls 12,64 Profit and loss account 2,52,57,59,69,71,76-77, 80-85,92,102,113,117,118,122,123,142,149 Property, plant and equipment 25,125 Provisions for liabilities and charges 60,61,80,90 R Reconciliation of equity of movements in equity shareholders’ funds 80,82 Registrar 153 Regulation 11,12 Remuneration Committee 34,40 Remuneration report 39-50 Report of the Directors 2-72 Research collaborations 21,110 Research and development accounting policy 83 animals and research 22 Consumer Healthcare 22 diseases of the developing world 21,27 expenditure 52,57,58,69,76,126,142 Pharmaceuticals 14-22 pipeline 14-17 Respiratory 7-10,15,17,20-22,53-57,66,67,82, 144-148 Return on capital employed 149 Revenue – accounting policy 83 Risk factors 64,65 Risk Oversight and Compliance Council (ROCC) 36 page page page S Sales Consumer Healthcare 52,57,69,86,134,135, 142,148 Pharmaceuticals 8,10,13,37,52-56,64-66,68, 69,86,142-148 SB Clinical laboratories 107,108 Segment information 6,86-88,132,134,135, 139-141,148 Selected financial data 71 Senior management – compensation and interests 50 Share buy-back 35,58,59,62,82,101,102 Share capital 35,50,79-81,101,125,128,150,154 Share premium 80,81,85,101,150 Share price 46,48,49,53,152-154 Share purchases 62,63 Share statistics 149 Shareholder information 153 Shareholder return 42,119,120,152 Shareholders’ funds 60,80,82 Shareholdings – analysis 155 Statement of total recognised gains and losses 76,77 T Taxation 58-61,70,76,78,81,83,85-89,91,92,97, 98,124,126,129,130,133,134,142 Taxation information for shareholders 156 Tax rate 52,58,65,70,85,91,130 Trade marks 5,23 Treasury operations 37,62,85 Treasury policies 62,63 Tuberculosis 27 U UK segment 88 US GAAP – reconciliation to US accounting principles 122-138 consolidated balance sheet 125 consolidated income statement 126,127 comprehensive income and changes in shareholders’ equity 126,127 consolidated statement of cash flows 124,128 earnings per share/ADS 133 material differences between UK and US GAAP 122-124 post-retirement benefits 123,136-138 purchase accounting 130,131 results under US accounting principles 72 segment information 134,135 selected financial data 71 taxation 133 V Vaccines 6-8,10,11,14,17,21,22,27,54-56,67-69 82,86,105,144-148 W World economy 53 World market 53
Contact details INTERNET Information for investors and about the company is available on GlaxoSmithKline’s corporate website at www.gsk.com HEAD OFFICE AND REGISTERED OFFICE GlaxoSmithKline plc 980 Great West Road Brentford Middlesex TW8 9GS Tel: +44 (0)20 8047 5000 UNITED KINGDOM Investor relations 980 Great West Road Brentford Middlesex TW8 9GS Tel: +44 (0)20 8047 5557 / 5558 Fax: +44 (0)20 8047 7807 Registrar Lloyds TSB Registrars The Causeway Worthing West Sussex BN99 6DA www.shareview.co.uk General enquiries, Annual Report orderline and Corporate Nominee service Tel: 0870 600 3991 inside the UK Tel: +44 (0)121 415 7067 outside the UK Shareholder Investment Plans Dividend re-investment enquiries Tel: 0870 241 3018 inside the UK Tel: +44 (0)1903 604 516 outside the UK Monthly Savings Plan enquiries Tel: 0870 606 0268 inside the UK Tel: +44 (0)131 527 3746 outside the UK ISA enquiries Tel: 0870 242 4244 inside the UK Tel: +44 (0)1903 604 594 outside the UK Glaxo Wellcome and SmithKline Beecham corporate PEPs The Share Centre Limited Oxford House Oxford Road Aylesbury Bucks HP21 8SZ Tel: +44 (0)1296 414 144 Corporate share dealing facility NatWest Stockbrokers Corporate & Employee Service 55 Mansell Street London E1 8AN Tel: 0870 600 3080 inside the UK Tel: +44 (0)20 7895 5923 outside the UK email: contactces@natwest.com quoting ‘GSK Shareholders Service’ UNITED STATES OF AMERICA Investor relations One Franklin Plaza PO Box 7929 Philadelphia PA 19101 Tel: 1 888 825 5249 toll free Tel: +1 215 751 7003 outside the USA Fax: +1 215 751 3233 ADR programme administrator The Bank of New York Shareholder Relations PO Box 11258 Church Street Station New York NY 10286-1258 www.adrbny.com Tel: 1 877 353 1154 toll free Tel: +1 610 312 5315 outside the USA Customer response center Tel: 1 888 825 5249 toll free Printed by St. Ives Westerham Press in the UK. The paper used in the production of this document is made from pulp harvested from sustainable forests, also using sawmill residues and forest thinnings. It is elemental chlorine-free.
Page 1 and 2:
Do more, feel better, live longer T
Page 3 and 4:
The Annual Report was approved by t
Page 5 and 6:
Joint statement by the Chairman and
Page 7 and 8:
04 GlaxoSmithKline Joint statement
Page 9 and 10:
Products - Pharmaceuticals Descript
Page 11 and 12:
Additionally, GlaxoSmithKline marke
Page 13 and 14:
Competition - Consumer Healthcare T
Page 15 and 16:
Operating activities Marketing and
Page 17 and 18:
Description of business GlaxoSmithK
Page 19 and 20:
Description of business GlaxoSmithK
Page 21 and 22:
Product approvals Country/Region Pr
Page 23 and 24:
As part of GlaxoSmithKline’s majo
Page 25 and 26:
Operating resources Intellectual pr
Page 27 and 28:
Compensation philosophy and program
Page 29 and 30:
Access to healthcare in the develop
Page 31 and 32:
GlaxoSmithKline gave unrestricted g
Page 33 and 34:
Corporate governance This section d
Page 35 and 36:
Corporate Executive Team (CET) JP G
Page 37 and 38:
The Annual General Meeting takes pl
Page 39 and 40:
Research and development Safety of
Page 41 and 42:
Remuneration report GlaxoSmithKline
Page 43 and 44:
The majority of the competitor pane
Page 45 and 46:
Performance graph 100 90 80 70 60 N
Page 47 and 48:
Non-Executive Directors Non-Executi
Page 49 and 50:
Non-Executive Directors’ share ar
Page 51 and 52:
Incentive plans Remuneration report
Page 53 and 54:
Operating and financial review and
Page 55 and 56:
2002 Year World economy The world
Page 57 and 58:
Pharmaceutical sales by therapeutic
Page 59 and 60:
Consumer Healthcare sales 2002 2001
Page 61 and 62:
Earnings 2001 2002 (restated) CER%
Page 63 and 64:
Contractual obligations and commitm
Page 65 and 66:
Funding, maturity and counterparty
Page 67 and 68:
Stricter regulatory controls also h
Page 69 and 70:
Operating and financial review and
Page 71 and 72:
Latin America reported eight per ce
Page 73 and 74:
Selected financial data UK/US GAAP
Page 75 and 76:
Financial statements GlaxoSmithKlin
Page 77 and 78:
Independent Auditors’ report to t
Page 79 and 80:
Consolidated statement of profit an
Page 81 and 82:
Consolidated statement of cash flow
Page 83 and 84:
Company balance sheet at 31st Decem
Page 85 and 86:
2 Accounting policies Consolidation
Page 87 and 88:
2 Accounting policies continued Sto
Page 89 and 90:
6 Segment information continued Not
Page 91 and 92:
7 Merger items, restructuring costs
Page 93 and 94:
Notes to the financial statements G
Page 95 and 96:
13 Earnings per share Notes to the
Page 97 and 98:
Page 99 and 100:
19 Equity investments Notes to the
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
30 Legal proceedings The Group is i
Page 107 and 108:
30 Legal proceedings continued In F
Page 109 and 110:
30 Legal proceedings continued In 2
Page 111 and 112: 31 Acquisitions and disposals conti
Page 113 and 114: 32 Financial instruments and relate
Page 115 and 116: 32 Financial instruments and relate
Page 117 and 118: 33 Employee costs continued Notes t
Page 119 and 120: 33 Employee costs continued Notes t
Page 121 and 122: 34 Employee share schemes continued
Page 123 and 124: 34 Employee share schemes continued
Page 125 and 126: 37 Reconciliation to US accounting
Page 129 and 130: Notes to the financial statements G
Page 141 and 142: 38 Principal Group companies Notes
Page 143 and 144: 38 Principal Group companies contin
Page 145 and 146: Financial record GlaxoSmithKline 14
Page 153 and 154: Investor information GlaxoSmithKlin
Page 155 and 156: Shareholder information Ordinary sh
Page 157 and 158: Share capital GlaxoSmithKline 155 A
Page 159 and 160: Cross reference to Form 20-F GlaxoS
Page 161: Index A Access to healthcare 27 Acc
show all

GSK Annual Report 2002

Create successful ePaper yourself

Delete template?

Save as template?